202 related articles for article (PubMed ID: 36265088)
41. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP; Geuzinge HA; Stout NK; Alagoz O; Hampton J; Kerlikowske K; de Koning HJ; Miglioretti DL; van Ravesteyn NT; Schechter C; Sprague BL; Tosteson ANA; Trentham-Dietz A; Weaver D; Yaffe MJ; Yeh JM; Couch FJ; Hu C; Kraft P; Polley EC; Mandelblatt JS; Kurian AW; Robson ME;
JAMA Oncol; 2022 Apr; 8(4):587-596. PubMed ID: 35175286
[TBL] [Abstract][Full Text] [Related]
42. Effect of implementing digital breast tomosynthesis (DBT) instead of mammography on population screening outcomes including interval cancer rates: Results of the Trento DBT pilot evaluation.
Bernardi D; Gentilini MA; De Nisi M; Pellegrini M; Fantò C; Valentini M; Sabatino V; Luparia A; Houssami N
Breast; 2020 Apr; 50():135-140. PubMed ID: 31607526
[TBL] [Abstract][Full Text] [Related]
43. Cost-Effectiveness of Care Environments for Improving the Mental Health of Orphaned and Separated Children and Adolescents in Kenya.
Wilson-Barthes M; Chrysanthopoulou SA; Atwoli L; Ayuku D; Braitstein P; Galárraga O
J Ment Health Policy Econ; 2021 Jun; 24(2):31-41. PubMed ID: 34151779
[TBL] [Abstract][Full Text] [Related]
44. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women.
Tina Shih YC; Dong W; Xu Y; Shen Y
Value Health; 2019 Feb; 22(2):185-193. PubMed ID: 30711063
[TBL] [Abstract][Full Text] [Related]
45. Cost differences between digital tomosynthesis and standard digital mammography in a breast cancer screening programme: results from the To-Be trial in Norway.
Moger TA; Swanson JO; Holen ÅS; Hanestad B; Hofvind S
Eur J Health Econ; 2019 Nov; 20(8):1261-1269. PubMed ID: 31399773
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening.
McDonald ES; Oustimov A; Weinstein SP; Synnestvedt MB; Schnall M; Conant EF
JAMA Oncol; 2016 Jun; 2(6):737-43. PubMed ID: 26893205
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of early detection of breast cancer in Catalonia (Spain).
Carles M; Vilaprinyo E; Cots F; Gregori A; Pla R; Román R; Sala M; Macià F; Castells X; Rue M
BMC Cancer; 2011 May; 11():192. PubMed ID: 21605383
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of breast cancer screening in women on dialysis.
Wong G; Howard K; Chapman JR; Craig JC
Am J Kidney Dis; 2008 Nov; 52(5):916-29. PubMed ID: 18789566
[TBL] [Abstract][Full Text] [Related]
50. Screening Performance of Digital Breast Tomosynthesis vs Digital Mammography in Community Practice by Patient Age, Screening Round, and Breast Density.
Lowry KP; Coley RY; Miglioretti DL; Kerlikowske K; Henderson LM; Onega T; Sprague BL; Lee JM; Herschorn S; Tosteson ANA; Rauscher G; Lee CI
JAMA Netw Open; 2020 Jul; 3(7):e2011792. PubMed ID: 32721031
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer.
Huang Y; Huang X; Huang X; Lin S; Luo S; Gu D; Weng X; Xu X
Hum Reprod; 2023 Jun; 38(6):1099-1110. PubMed ID: 37075316
[TBL] [Abstract][Full Text] [Related]
52. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
[TBL] [Abstract][Full Text] [Related]
53. Breast MRI screening for average-risk women: A monte carlo simulation cost-benefit analysis.
Mango VL; Goel A; Mema E; Kwak E; Ha R
J Magn Reson Imaging; 2019 Jun; 49(7):e216-e221. PubMed ID: 30632645
[TBL] [Abstract][Full Text] [Related]
54. Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study.
Oeffinger KC; Ford JS; Moskowitz CS; Chou JF; Henderson TO; Hudson MM; Diller L; McDonald A; Ford J; Mubdi NZ; Rinehart D; Vukadinovich C; Gibson TM; Anderson N; Elkin EB; Garrett K; Rebull M; Leisenring W; Robison LL; Armstrong GT
J Clin Oncol; 2019 Aug; 37(24):2131-2140. PubMed ID: 31260642
[TBL] [Abstract][Full Text] [Related]
55. The cost-effectiveness of screening for oral cancer in primary care.
Speight PM; Palmer S; Moles DR; Downer MC; Smith DH; Henriksson M; Augustovski F
Health Technol Assess; 2006 Apr; 10(14):1-144, iii-iv. PubMed ID: 16707071
[TBL] [Abstract][Full Text] [Related]
56. The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria.
Schiller-Fruehwirth I; Jahn B; Einzinger P; Zauner G; Urach C; Siebert U
Value Health; 2017 Sep; 20(8):1048-1057. PubMed ID: 28964436
[TBL] [Abstract][Full Text] [Related]
57. Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore.
Wong JZY; Chai JH; Yeoh YS; Mohamed Riza NK; Liu J; Teo YY; Wee HL; Hartman M
BMC Health Serv Res; 2021 Apr; 21(1):379. PubMed ID: 33892705
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study.
Chootipongchaivat S; Wong XY; Ten Haaf K; Hartman M; Tan KB; van Ravesteyn NT; Wee HL
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):653-660. PubMed ID: 33531436
[TBL] [Abstract][Full Text] [Related]
59. Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer.
Ehrhardt MJ; Ward ZJ; Liu Q; Chaudhry A; Nohria A; Border W; Fulbright JM; Mulrooney DA; Oeffinger KC; Nathan PC; Leisenring WM; Constine LS; Gibson TM; Chow EJ; Howell RM; Robison LL; Armstrong GT; Hudson MM; Diller L; Yasui Y; Armenian SH; Yeh JM
J Clin Oncol; 2020 Nov; 38(33):3851-3862. PubMed ID: 32795226
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
